Brokerages Set Halozyme Therapeutics, Inc. (NASDAQ:HALO) Price Target at $61.44

Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) have earned a consensus rating of “Moderate Buy” from the ten analysts that are currently covering the firm, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $60.89.

Several research analysts recently issued reports on the company. Piper Sandler increased their price objective on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research note on Friday, January 10th. Wells Fargo & Company dropped their price target on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. HC Wainwright lifted their price objective on Halozyme Therapeutics from $68.00 to $70.00 and gave the company a “buy” rating in a report on Friday, January 10th. JMP Securities raised their target price on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research report on Friday, November 1st. Finally, Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th.

Halozyme Therapeutics Stock Performance

HALO stock opened at $54.80 on Monday. Halozyme Therapeutics has a twelve month low of $33.15 and a twelve month high of $65.53. The firm has a market cap of $6.97 billion, a price-to-earnings ratio of 18.15, a PEG ratio of 0.40 and a beta of 1.24. The business’s fifty day simple moving average is $49.62 and its two-hundred day simple moving average is $54.12. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32.

Insider Activity at Halozyme Therapeutics

In related news, Director Jeffrey William Henderson sold 10,000 shares of the business’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $50.01, for a total transaction of $500,100.00. Following the completion of the transaction, the director now directly owns 43,611 shares of the company’s stock, valued at $2,180,986.11. The trade was a 18.65 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 2.70% of the stock is currently owned by company insiders.

Institutional Trading of Halozyme Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of HALO. Congress Asset Management Co. grew its position in shares of Halozyme Therapeutics by 446.5% in the 3rd quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company’s stock valued at $139,298,000 after buying an additional 1,988,238 shares during the last quarter. Handelsbanken Fonder AB grew its holdings in shares of Halozyme Therapeutics by 76.9% during the third quarter. Handelsbanken Fonder AB now owns 1,969,169 shares of the biopharmaceutical company’s stock worth $112,715,000 after purchasing an additional 856,200 shares during the last quarter. Janney Montgomery Scott LLC grew its holdings in shares of Halozyme Therapeutics by 698.8% during the fourth quarter. Janney Montgomery Scott LLC now owns 287,731 shares of the biopharmaceutical company’s stock worth $13,756,000 after purchasing an additional 251,711 shares during the last quarter. Boston Trust Walden Corp increased its position in shares of Halozyme Therapeutics by 54.0% during the third quarter. Boston Trust Walden Corp now owns 682,616 shares of the biopharmaceutical company’s stock worth $39,073,000 after purchasing an additional 239,321 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in shares of Halozyme Therapeutics by 12.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,897,759 shares of the biopharmaceutical company’s stock valued at $99,363,000 after purchasing an additional 209,530 shares during the period. 97.79% of the stock is currently owned by institutional investors and hedge funds.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.